CD274 and neoplasm: While tumor characteristics, such as programmed death-ligand 1 (PD-L1) expression, tumor mutational burden, and tumor-infiltrating lymphocyte status, are well-established predictive biomarkers for immunotherapy response, the role of sexual dimorphism is yet to be further described.